UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2016.
Commission File Number: 000-53805
Intellipharmaceutics
International Inc.
(Translation of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W
5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Only the statements in respect of the anticipated timing of the filing of the Rexista® XR (oxycodone hydrochloride) new drug application currently expected to be filed by Intellipharmaceutics International Inc. (the “registrant”) during its fiscal fourth quarter of 2016 set forth in the attached exhibit 99.1 shall be incorporated by reference into the registrant's effective Registration Statements on Form F-3, as amended and supplemented (Registration Statement Nos. 333-172796 and 333-196112), filed with the Securities and Exchange Commission, from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by the registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934. Except for the foregoing, no other document or portion of document furnished with this Form 6-K is incorporated by reference into the above-referenced Registration Statements.
Any projections and/or illustrative examples, as the case may be, contained in exhibit 99.1 are included solely to provide certain overview information concerning the variable potential financial results of drug commercialization in this industry sector when certain assumptions are used, and how those results could impact the potential future operating results of the registrant. No assurance can be made that such results will be achieved. The registrant may conduct its business in a manner different from that set forth in the assumptions, as changing circumstances may require. Actual results of operations are likely to vary from the projections and the variations may be material and adverse. The projections should not be regarded as a representation or prediction that the registrant will achieve or is likely to achieve any particular results. Without limiting the generality of the foregoing, no assurance can be given as to whether or when the registrant will receive regulatory approval for any of the registrant’s product candidates.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Intellipharmaceutics International
Inc.
| ||
| Date: September 13, 2016 |
/s/ Domenic Della Penna
|
EXHIBIT LIST
| Exhibit | Description |
| 99.1 | Presentation – Rodman & Renshaw Global Investment Conference – September 13, 2016 |